



Produits sanguins
Cellules souches
Tissus humains

November 7th 2019

BY ELECTRONIC MAIL

Request for collaboration from Héma-Quebec to avoid the expiration of FEIBA 1000 IU

Following the introduction last June of the product HEMLIBRA[®], injectable emicizumab for the treatment of patients with hemophilia A with the presence of inhibitors, a large quantity of FEIBA 1000 UI accumulated in the province of Québec, due to unplanned circumstances in the transition.

In order to avoid the loss of these precious plasma derived products, from an ethical and financial standpoint, and further to discussions initiated with certain specialists in Hemophilia Centers in Alberta and Ontario, HÉMA-QUÉBEC is requesting the collaboration of the Hemophilia Centers served by Canadian Blood Services, by the substitution of vials of FEIBA 2500 UI with vials of FEIBA 1000 UI.

HÉMA-QUÉBEC thanks you in advance for all efforts that you would make to help address this exceptional situation.

Please accept our sincere salutations.

Christine Ouimet, Vice-President, Supply chain

- c. c. Dr Stéphanie Cloutier, Présidente, Association des CTH du Québec
Dr Georges-Étienne Rivard, Directeur hémophilie, CHU Ste-Justine
Dr Vincent Laroche, CHU Québec
Jean Lapierre, Héma-Québec
Rima Khalil, Héma-Québec